NASDAQ:ELOX

Eloxx Pharmaceuticals Q3 2026 Earnings Results & Report

Eloxx Pharmaceuticals logo
$12.75 -0.40 (-3.04%)
As of 04:00 PM Eastern

Eloxx Pharmaceuticals reported Q3 2026 earnings on November 13, 2026. The company reported EPS of -$0.49.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Eloxx Pharmaceuticals EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eloxx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eloxx Pharmaceuticals Q3 2026 Earnings FAQ

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported earnings of -$0.49 per share for Q3 2026. The report was announced on Friday, November 13, 2026.

Eloxx Pharmaceuticals Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Eloxx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eloxx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eloxx Pharmaceuticals and other key companies, straight to your email.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals (NASDAQ:ELOX) was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production.

The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations. ELX-02 was investigational and was not a marketed treatment.

In 2024, Eloxx completed a business combination with Zenas BioPharma, and the combined company began operating under the Zenas BioPharma name.

View Eloxx Pharmaceuticals Profile